Effects on Endocrine-Metabolic Parameters and Body Composition of the Addition of Low-Dose Pioglitazone to Flutamide-Metformin Therapy in Young Women with Hyperinsulinemic Ovarian Hyperandrogenism and Cardiovascular Risk - Pioglitazone in PCOS

Hospital Sant Joan de Déu0 个研究点目标入组 40 人开始时间: 2005年10月5日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•1-age 18 years or above
•2-menarche at least 3 yr before study start
•3-hyperandrogenism, either clinical (hirsutism, acne, menstrual disturbances) or biochemical (increased testosterone, decreased sex hormone-binding globulin, SHBG), or increase free androgen index).
•4-hyperinsulinism: increase serum fasting insulin levels (15 uU/mL or more), decreased glucose/insulin ratio (<7), or increased insulin responses (>100 uU/mL) to an oral glucose overload.
•5-dyslipidemia: decreased HDL-cholesterol; increased LDL-cholesterol and tryglicerides
•6-neutrophilia (>3,7 x mm3); increased CRP (> 2mg/L).
•7-normal liver, kidney and adrenal functions
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•1-age less than 18
•2-pregnancy
•3-hyperprolactinemia, Cushing's syndrome, thyroid dysfunction, liver, kidney or adrenal disease, inflammatory bowel disease, family or personal history of diabetes mellitus or glucose intolerance, abnromal echocardiography
•4-therapy with anti-androgens, estroprogestagens, antibiotics, or drugs interfering with glucose and lipid metabolism or gonadal function (over the last 6 mo)
•5-alcoholism

发起方